Gilead Sciences Inc (WBO:GILD)
€ 82.34 -0.83 (-1%) Market Cap: 103.30 Bil Enterprise Value: 122.22 Bil PE Ratio: 109.56 PB Ratio: 6.12 GF Score: 77/100

Q2 2019 Gilead Sciences Inc Earnings Call Transcript

Jul 30, 2019 / 08:30PM GMT
Release Date Price: €60.4 (-0.36%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences' Second Quarter 2019 Earnings Conference Call. My name is Liz, and I will be your conference operator today. (Operator Instructions) And as a reminder, this conference call is being recorded.

I would now like to turn the call over to Sung Lee, Senior Vice President of Investor Relations. Please go ahead.

Sung Lee
Gilead Sciences, Inc. - VP of IR

Thank you, Liz, and good afternoon, everyone. Just after market close today, we issued a press release with earnings results for the second quarter 2019. The press release and detailed slides are available on the Investor Relations section of the Gilead website.

The speakers on today's call will be Daniel O'Day, Chairman and Chief Executive Officer; Johanna Mercier, Chief Commercial Officer; and Robin Washington, Executive Vice President and Chief Financial Officer. Also in the room are Diana Brainard, Senior Vice President and Head of our HIV and Emerging Viruses Therapeutic Area; and John Sundy, Senior Vice

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot